Stoke Therapeutics, Inc. — Director's Dealing 2021

Jan 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Stoke Therapeutics, Inc. (STOK)
CIK: 0001623526
Period of Report: 2020-08-13

Reporting Person: Menzel Garry E (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-08-13	Director Stock Option (Right to Buy)	$28.57	A	29555	Acquired	2030-08-13	Common Stock (29555)	Direct

Footnotes

F1: The option vested as to 1/12th of the total shares on November 13, 2020, and then 1/12th of the total shares vest quarterly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.